Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis

Inclusion Criteria

• •Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma
• •Tumor with measurable contrast enhancement (at least 15 mm in diameter)
• •Surgical procedure limited to a biopsy or partial excision
• •In the event of partial excision, an early postoperative check-up (\<72 hours) performed at best by MRI, if not by CT, is required.
• •Time between surgery and inclusion less than or equal to one and a half months (45 days)
• •Age\> 18 years old; \<70
• •Karnofsky index\> 60
• •Stable or reduced dose of corticosteroids in the 15 days prior to inclusion
• •Polynuclear neutrophils\> 1500; platelets\> 100,000
• •Bilirubin \<1.25 x UNL; SGOT, SGPT, PAL \<2.5 x UNL
• •Absence of serious uncontrolled pathology
• •Patient having received and understood the information and having signed the consent